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Abstract
Herein we present the development of asymmetric deacylative allylation of ketone enolates. The
reaction directly couples readily available ketone pronucleophiles with allylic alcohols using facile
retro-Claisen cleavage to form reactive intermediates in situ. The simplicity and robustness of the
reaction conditions is demonstrated by the preparation of > 6 grams of an allylated tetralone from
commercially available materials. Furthermore, use of non-racemic PHOX ligands allows
intermolecular formation of quaternary stereocenters directly from allylic alcohols.
The asymmetric allylation of ketone enolates to form α-quaternary ketones has recently
garnered significant attention from the synthetic community.1-12 The synthetic flexibility of
the product ketones has led to the use of these methods in complex molecule
synthesis.10,13-17 The most commonly utilized method for preparing α-quaternary α-
allylated ketones is Pd-catalyzed asymmetric allylic alkylation (AAA). First, Trost reported
the AAA of nonstabilized ketone enolates (pKa > 24) involving the allylation of tetralones
with allylic acetates in the presence of LDA with or without Me3SnCl.3-5 More recently,
asymmetric decarboxylative allylation (DcA) methods were reported, which allowed similar
allylation in the absence of base and other additives (Scheme 1).6-17 Although DcA is an
attractive advancement, the required substrates A and B necessitate coupling of the allyl
electrophile with the enolate nucleophiles prior to DcA. This process is not ideal because it
requires one to control O vs. C alkylation using allyl chloroformate derivatives that are not
readily available with a variety of substitution patterns.
Recently, we have developed deacylative allylation (DaA) as a robust approach to
thesynthesis of allylated chemical building blocks (Scheme 2).18,19 This intermolecular
coupling allows the direct allylation of ketone pronucleophiles (derived from simple active
methylene compounds C) with readily available allylic alcohols,20-26 and generates little
waste product. DaA takes advantage of the facile retro-Claisen reaction of α,α-disubstituted
active methylene compounds to generate enolates and allylic acetates in situ.27-31 In other
words, retro-Claisen cleavage results in the formation of the active nucleophile and
simultaneously activates the electrophile toward palladium-catalyzed coupling. One example
of its utility, we have previously demonstrated DaA's ability to construct 1,6-dienes
(cycloisomerization substrates32-39) in a single pot via sequential palladium-catalysis.18-19,40
Herein, we report the use of the DaA concept for the asymmetric allylic alkylation of
nonstabilized ketone enolates. To demonstrate the scalability of DaA, we report a > 6 gram
scale reaction. In addition, we report the asymmetric synthesis of various 1,6-heptadienes
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(72-95% ee) as well as the synthesis of an intermediate en route to the biologically active
natural product (+)- hamigeran.14,41 We also outline an approach to either enantiomer of
chiral 1,6-heptadienes using the same chiral catalyst.
To begin, it was deemed important to utilize ketone reactants that are readily available from
inexpensive starting materials. With this in mind, we synthesized precursors using Claisen
condensations of α-tetralone with ethyl formate (1a), acetic anhydride (1b), and propanoic
anhydride (1c) (Table 1).42,43 It is important to point out that the simple, high-yielding
Claisen condensations yield active methylene compounds that undergo mild acetoacetic
ester-type alkylation. With 1a-c in hand, we screened conditions for DaA. The formyl
derivative (1a) provided a good yield of allylated product 2a, but significant quantities of
protonation product were also produced. The amount of protonation could be attenuated by
use of bidentate rac-BINAP (entry 2), but could not be avoided entirely. The protonation
product could arise from palladium-catalyzed reduction by formate ion.44-46 With this in
mind, the diketones 1b-c were subjected to the reaction conditions. Using these ketones,
Pd(PPh3)4 was an active catalyst for DaA and little protonation side reaction took place
(Table 1, entries 3-4).
With the reaction conditions in hand, we set out to examine the scope of the DaA reaction
(Table 2). Simple allyl and β-substituted allyl alcohols performed well in the reaction
(2a-2c). An acrylate could likewise be incorporated without competing conjugate additions
of alkoxide or enolate (2c). Unfortunately, low yields were observed with terminally
substituted allyl alcohol coupling partners such as cinnamyl alcohol.
Aside from α-methyl substitution such as that in 2a, allylic systems could be easily
incorporated via Tsuji-Trost allylation prior to DaA (2b-2k). The use of Tsuji-Trost
allylation prior to DaA highlights an important advantage of DaA as compared to
decarboxylative allylation: The ketone substrates for DaA are compatible with a variety of
metal-catalyzed couplings (including Tsuji-Trost) that are incompatible with the allyl ester/
carbonate structures required for DcA. Due to the robust nature of the Tsuji-Trost allylation,
a diverse pool of bisallylated α-tetralones could be prepared. Related 1,6-heptadienes
undergo a wide variety of cycloisomerization and cycloaddition reactions.32-39 With regard
to the R1 substituent introduced via Tsuji-Trost allylation, terminal (2g) and β-aryl (2d)
substitution on the allyl motif were allowed. Importantly, the synthetically useful
cyclopropylallyl (2h) moiety could be incorporated, allowing for the rapid synthesis of a
unique precursor for [5+2] cycloaddition.39 Other important allylic acetates could also be
incorporated via Tsuji-Trost allylation. For example, crotyl (2f), cinnamyl (2g), prenyl (2i),
geranyl (2k), and myrtenyl (2j) carbon skeletons could be incorporated on to the tetralone
scaffold.
Regarding the tetralone core, electron withdrawing (e.g., fluoro, 2l) and donating (2m,n)
groups were compatible. Aside from tetralone cores, both indanone (2o) and benzosubarone
(2p) were compatible substrates.
Since the starting materials for DaA are commercially available and/or easily prepared,
many of the products in Table 2 were prepared on the > 0.5 gram scale (Table 2, footnote b).
To better test the scalability of the DaA reaction, we further developed the protocol for
multi-gram synthesis (Table 2, 2q). We prepared > 6 grams of 2q using allyl alcohol as a
coupling partner and were able to reduce the loadings of Pd (0.5 mol%) and base (1.5
equiv.).
Next we turned our attention to the development of an asymmetric reaction to synthesize
enantioenriched 2a (Table 3). We were pleased to see that useful ee's (79-85 % ee) could be
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achieved using the formyl, acetyl, and propanoyl cleaving groups (1a-c) by utilizing the
commercially available t BuPHOX ligand L1 (entries 1-3).
While the acetyl group provided the highest ee (entry 2), the enantioselectivity of the
coupling was not strongly dependent on the cleaving group. Importantly, excess alkoxide
had a detrimental effect on the ee (entry 4) and thus the acetyl tetralone must be used in
slight excess (1.05 equiv) compared to alkoxide. One potential explanation for this
observation is that excess alkoxide competes with the enolate for coordination to palladium.
Such a process would interfere with the inner-sphere mechanism for allylation as proposed
by Stoltz.47 Lastly, commercially available t BuPHOX derivative L2 was a significantly
poorer ligand (58-62 % ee, entries 5-6) in this transformation.
To demonstrate the scope of this asymmetric variant, we prepared an assortment of
enantioenriched 1,6-heptadienes (Table 4). The 1,6-heptadienes were prepared by 2-step
Tsuji-Trost/asymmetric DaA. One advantage of sequential allylation is that either
enantiomer of the product can be prepared by simply interconverting the two allylic
coupling partners (e.g. 2b and ent-2b, Table 4). It is noteworthy that the yield and ee of
ent-2b was superior using the fluorinated tert-butyl PHOX ligand L3. This type of ligand
has been shown by Stoltz to be particularly useful for sluggish allylation reactions.48,49 In
our hands we noticed a similar reaction efficiency increase. As before, important naturally
occurring allylic carbon chains such as prenyl (2i) and geranyl (2k) groups could also be
incorporated.
In addition to the heptadiene synthesis, DaA was also utilized to synthesize a key
intermediate used for the synthesis of (+)-hamigeran. The synthesis of the Clive-Stoltz
intermediate 2n (Scheme 2) proceeded via acetylation and methylation of the known
tetralone 4. The asymmetric deacylative allylation reaction went without incident providing
the required intermediate 2n in high yield (93%) and ee (86%). DaA provides intermediate
2n in similar yield and ee to that achieved by Stoltz using the same ligand under similar
conditions.50 It is important to point out that Stoltz and coworkers, using a different ligand,
can achieve increased ee (91-94%).50 That said, the DaA route has several advantages. First,
the prior methods for preparing 2n, introduce the α-methyl group by a cryogenic LDA/
HMPA mediated methylation.14,41 Our DaA method allows alkylation under simple K2CO3
mediated alkylation conditions. Secondly, the decarboxylative coupling method also
requires the 2-step allyl enol carbonate formation (with allyl chloroformate) followed by
asymmetric DcA. The DaA method reported herein allows the intermolecular introduction
of the allyl group directly from allyl alcohol with the potential for analoging.
To conclude, we have developed a new method for allylic alkylation of α-tetralones via
deacylative allylation. The reaction directly couples readily available ketone pronucleophiles
with allylic alcohols using facile retro-Claisen cleavage to form reactive intermediates in
situ. The simplicity and robustness of the reaction conditions is demonstrated by the
preparation of > 6 grams of an allylated tetralone in one pot from commercially available
materials. Furthermore, use of non-racemic PHOX ligands allows intermolecular formation
of quaternary stereocenters directly from allylic alcohols. To demonstrate the utility of this
new reaction, enantioenriched 1,6-heptadienes as well as a key intermediate in the synthesis
of (+)-hamigeran were prepared.
Experimental Section
General Experimental Methods
All reactions were run under an argon atmosphere using a Schlenk-argon line, unless noted.
Pd(PPh3)4 and Pd2dba3 was purchased from Strem, stored in a glove box and used as is.
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PHOX ligands were purchased from Aldrich or prepared by the known literature
procedures.48,49 THF was distilled over Na using benzophenone as an indicator. Allyl
alcohol and β-methylallyl alcohol were purchased from Aldrich, stored over 3Å MS in a
sealed vial equipped with a rubber septum for removal by syringe. Acetyltetralones were
prepared by their literature procedure.42-43 All other substrates were prepared according to
the procedures outlined below in the experimental section. 2-acetyltetralone 1 is
commercially available from Aldrich. It can also be prepared by the Claisen condensation
(see procedure below). 4 was prepared by the literature procedures.14,41
Chiral separation was performed on an HPLC instrument using an OD-H chiracel column.
Stereochemical configuration is based on Stoltz's assignment as retention times, chiral
column (chiracel OD-H), and catalyst ((S)-tBuPHOX) were the same with same products
(e.g. 2a, 2n).7,14
General procedure (small scale) for racemic deacylative allylation: Synthesis of 2a
A flame-dried 10mL Schlenk flask equipped with a stir bar was brought into a glove box
and charged with NaH (2 equiv. 0.50, 12mg) and Pd(PPh3)4 (2.5 mol%, 0.0063 mmol, 7.2
mg). The flask was capped, removed from the glove box and attached to a argon line. 4 mL
of dry THF was added to the flask and allyl alcohol (0.25 mmol, 15 mg) and tetralone 1b
(0.255 mmol, 51 mg) were added in that order. Both syringes used to transfer reagents were
washed with the reaction mixture solvent and reinjected. The vessel was capped, wrapped in
parafilm and the system was completely sealed over argon and allowed to react for 5h.
After the allotted reaction time as determined by TLC (5h), the reaction mixture was diluted
with 15% EtOAc in hexanes and filtered through a SiO2 plug with excess (50-75 mL) of the
15% EtOAc in hexanes solvent mixture. The solvent was evaporated and subjected to silica
gel chromatography (3% EtOAc in Hexanes) to yield the pure product 2a.
General procedure for asymmetric deacylative allylation: synthesis of enantioenriched 2a
Two flame-dried 10mL Schlenk flasks equipped with stir bars were flame dried and brought
into a glove box. The catalyst (Pd2 dba3, 1.25 mol % 0.0063 mmol, 5.7 mg and tert-
butylPHOX ligand, 3 mol%, 0.015 mmol, 6 mg) was loaded into one flask and NaH (2
equiv., 1 mmol, 25 mg) was loaded into the other. Both were capped, removed from the
glove box and attached to a Schlenk argon line. 2mL of dry THF was added to the catalyst
flask, which was then stirred for 10 min at 40 °C. In the meantime, 3 mL of dry THF was
added to the flask containing NaH. To the NaH containing flask was added allyl alcohol (via
syringe, 0.50 mmol, 29mg) and tetralone derivative 1a (via syringe, 0.51 mmol, 95mg) in
that order. Both syringes used to transfer reagents were washed with the reaction mixture
solvent and reinjected. Directly after the final reagent addition, the preformed catalyst was
then transferred via syringe and injected as a shot (no need to wash this syringe). The vessel
was capped, wrapped in parafilm and the system was completely closed and allowed to react
for 5h.
After the allotted reaction time as determined by TLC (12h), the reaction mixture was
diluted with 15% EtOAc in hexanes and filtered through a SiO2 Plug with excess (50-75mL)
of the 15% EtOAc in hexanes solvent mixture. The solvent was evaporated and subjected to
silica gel chromatography (3% EtOAc in Hexanes) to yield the pure product 2a.
General procedure (large scale) for deacylative allyation: Synthesis of 2q
A flame-dried 200 mL Schlenk flask was equipped with an egg-shaped stir bar and brought
into a glove box where it was charged with NaH (95% purity, 1.5 equiv., 35.3 mmol, 890
mg) and Pd(PPh3)4 (0.5 mol%, 0.118 mmol, 136 mg). The flask was capped, removed from
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the glove box, and attached to an argon line. 25 mL of THF was added and the
heterogeneous mixture was chilled to 0 °C in an ice bath. Allyl alcohol (23.5 mmol, 1.364 g)
was then added neat dropwise over 5 minutes. The flask was allowed to warm to room-
temperature, and upon ceased H2 (g) effervescence, was re-chilled to 0 °C in an ice bath.
Substrate ketone (23.5 mmol, 7.14 g) was dissolved in 15 mL of THF and added dropwise
over ～5 min. The transfer vessel and syringe were rinsed with 2 × 5 mL portions of dry
THF to ensure complete transfer of the ketone to the reaction vessel. The reaction vessel was
then sealed, equipped with an empty balloon (a small amount of pressure builds up over
time), removed from the ice bath, and allowed to react at room temperature for 16 – 18 h.
After the allotted reaction time, the reaction mixture was diluted with 100 mL of a 1:4
mixture of ethyl acetate and hexanes and filtered through a pad of silica gel using vacuum
filtration. The reaction vessel was washed with 4 × 100 mL portions of the ethyl acetate and
hexanes mixture. The filtrate was collected and rotary evaporation yielded the crude
product.
The crude product was purified by silica gel column chromatography (～ column size 3 cm
diameter × 20 cm height, mobile phase ～2 L of 2.0 % EtOAc in hexanes) yielding the
desired product as a viscous yellow oil (6.18 g, 87% yield) as well as ～0.8 g of an 85% pure
fraction.
General procedure for methylation of diketones
A 25mL Schlenk flask equipped with a stir bar was charged with anhydrous K2CO3 and
attached to an argon line. The substrate (2.5 mmol) was added followed by 5 mL of
anhydrous DMSO. 500 μL of MeI was then added over 0.5 min. The vessel was capped and
stirred for 30 min.
After the allotted reaction time, the reaction mixture was diluted with 15mL of EtOAc and
transferred to a seperatory funnel. The vessel was washed with an extra 15mL EtOAc to
ensure complete transfer of its contents. The organic layer was washed with 2 × 50mL
portions of 1N HCl. The organic layer was dried, evaporated, and subjected to column
chromatography to yield the pure methylated ketone.
General procedure 1 for Tsuji-Trost allylation
In a glove box, a flame-dried Schlenk flask equipped with a stir bar was charged with 1
equiv. NaH and 1 mol% Pd(PPh3)4. The vessel was capped and removed from the glove box
and attached to an argon line. THF (0.2M) was added followed by 2-acetyltetralone (1
equiv.) was added to the flask. After the rapid effervescence, allyl acetate derivative (1.2
equiv.) was added and the reaction was heated at 40 °C until reaction was complete (as
monitored by TLC or GC-MS). Following complete coupling, the reaction mixture was
transferred to a seperatory funnel, diluted with EtOAc and extracted with 0.5 M HCl (2 × 10
mL) and brine (1 × 20 mL). The organic layer was dried over MgSO4, volatile organics were
removed by rotary evaporation and the residue was subjected to column chromatography
yielding the pure allylated 2-acetyltetralone derivative.
General procedure 2 for Tsuji-Trost allylation
In a glove box, a flame-dried Schlenk flask equipped with a stir bar was charged with 1 mol
% Pd(PPh3)4. The vessel was capped and removed from the glove box and attached to an
argon line. K2 CO3 (5 equiv.), DMSO (0.2M) and 2-acetyltetralone (1 equiv.) were added
sequentially. While stirring, the allyl acetate derivative (2.5-3 equiv.) was added and the
vessel was capped and stirred at 40 °C until reaction completion (as monitored by TLC or
GC-MS). Following complete coupling, the reaction mixture was transferred to a seperatory
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funnel, diluted with EtOAc and extracted with 0.5 M HCl (2 × 10 mL) and brine (1 × 20
mL). The organic layer was dried over MgSO4, volatile organics were removed by rotary
evaporation and the residue was subjected to column chromatography yielding the pure
allylated 2-acetyltetralone derivative.
Baylis-Hillman synthesis of tert-butyl 2-(hydroxymethyl)acrylate
A 250 mL round-bottom flask equipped with a stir bar was charged with DABCO (50 mmol,
5.6 g). 30 mL of H2 O was then added followed by paraformaldehyde (100 mmol, 3.03 g).
MeCN was then added with heating at 80 °C until the reaction mixture is homogeneous
(～30 mL). Tert-butyl acrylate (50 mmol, 6.4 g, 7.3 mL) was then added as a single shot.
The resulting reaction mixture was heated for 2.5 h.
After the allotted reaction time, the reaction mixture was diluted with 100 mL of DCM and
transferred to a seperatory funnel. An additional 100 mL DCM is used to wash the reaction
vessel to ensure complete transfer. The DCM layer was then washed with 100 mL of 1N
HCl followed by brine (50 mL). The volatiles were removed by rotary evaporation and the
crude oil was subjected to column chromatography (20% EtOAc in hexanes) to yield the
desired product.
2a:6 Isolated as a yellow oil (0.25 mmol scale, 0.045 g, 90%). 1H NMR (500 MHz, CDCl3):
δ 7.97 (dd, J = 7.9, 1.1 Hz, 1H), 7.39 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.8 Hz, 1H), 7.15
(d, J = 7.6 Hz, 1H), 5.72 (m, 1H), 5.02 (s, 1H), 5.00 (dm, J = 8.65 Hz, 1H), 2.91 (dd, J =
12.1, 5.1 Hz, 2H), 2.40 (dd, J = 13.8, 7.3 Hz, 1H), 2.21 (ddt, J = 13.8, 7.5, 1.1 Hz, 1H), 2.01
(m, 1H), 1.84 (ddd, J = 13.7, 7.1, 5.5 Hz, 1H), 1.12 (s, 3H).
13C NMR (126 MHz, CDCl3): δ 202.1, 143.3, 133.9, 133.1, 131.6, 128.7, 128.0, 126.6,
118.2, 44.6, 41.1, 33.3, 25.3, 21.9. HPLC: Chiracel OD-H column, mobile phase =
Hexanes : 2-propanol 99.7 : 0.3, flow rate = 0.4 μL/min
2b: Isolated as a yellow oil (0.3 mmol scale, 0.049 g, 68%). 1H NMR (500 MHz, CDCl3): δ
7.98 (dd, J = 7.9, 1.1 Hz, 1H), 7.39 (td, J = 7.5, 1.4 Hz, 1H), 7.24 (t, J = 7.51 Hz, 1H), 7.15
(d, J = 7.6 Hz, 1H), 5.72 (m, 1H), 5.03 (dm, J = 4.61 Hz, 1H), 5.00 (dm, J = 14.02 Hz, 1H),
2.92 (m, 2H), 2.67 (d, J = 13.6 Hz, 1H), 2.44 (dt, J = 13.9, 7.03, 1.03 Hz 1H), 2.16 (m, 2H),
1.98 (ddd, J = 13.9, 8.6, 5.3 Hz, 1H), 1.90 (ddd, J = 14.0, 6.4, 5.3 Hz, 1H), 1.53 (s, 3H). 13C
NMR (126 MHz, CDCl3): δ 200.0, 142.1, 141.4, 132.9, 132.1, 131.0, 127.6, 127.1, 125.7,
117.5, 114.0, 46.7, 41.7, 39.1, 29.2, 24.1, 23.4. HRMS data: Calc. for C17H20 O (M + H) =
241.1592. Found 241.1581; HPLC: Chiracel OD-H column, mobile phase = hexanes : 2-
propanol 99.6 : 0.8, flow rate = 0.4 μL/min
2c: Isolated as a yellow oil (2.0 mmol scale, 0.550 g, 81%) 1H NMR (500 MHz, CDCl3): δ
7.96 (dd, J = 7.9, 1.2 Hz, 1H), 7.38 (td, J = 7.51, 1.4 Hz, 1H), 7.23 (t, J = 7. 73 Hz, 1H), 7.14
(d, J = 7.6 Hz, 1H), 6.09 (d, J = 1.8 Hz, 1H), 5.45 (s, 1H), 4.74 (s, 1H), 4.61 (s, 1H), 3.02
(ddd, J = 17.0, 9.3, 4.8 Hz, 1H), 2.88 (dt, J = 17.05, 5.76 Hz, 1H), 2.74 (d, J = 13.8 Hz, 1H),
2.71 (d, J = 13.8 Hz, 1H), 2.61 (d, J = 13.4 Hz, 1H), 2.08 (m, 1H), 2.02 (d, J = 13.7 Hz, 1H),
1.78 (ddd, J = 14.0, 6.4, 4.9 Hz, 1H), 1.52 (s, 3H), 1.35 (s, 9H). 13C NMR (126 MHz,
CDCl3): δ 200.2, 166.9, 143.1, 142.4, 138.3, 133.1, 132.4, 128.6, 128.1, 126.6, 115.4, 80.6,
48.7, 43.9, 36.4, 30.2, 27.9, 25.3, 24.5. HRMS data: Calc. C22H28 O3 (M + Na = 363.1936),
found 363.1914
2d: Isolated as a yellow oil (0.27 mmol scale, 0.051 g, 62%). 1H NMR (500 MHz, CDCl3):
δ 7.80 (dd, J = 7.9, 1.1 Hz, 1H), 7.35 (td, J = 7.5, 1.4 Hz, 1H), 7.19 (m, 8H), 7.09 (d, J = 7.6
Hz, 1H), 5.63 (m, 1H), 5.20 (d, J = 1.7 Hz, 1H), 5.03 (s, 1H), 4.96 (dm, J = 10.21 1H), 4.90
(dm, J = 17.0, 1.3 Hz, 1H), 2.95 (d, J = 13.9 Hz, 1H), 2.81 (m, 2H), 2.75 (d, J = 13.9 Hz,
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1H), 2.43 (dd, J = 14.0, 6.7 Hz, 1H), 2.06 (dd, J = 14.0, 7.9 Hz, 1H), 1.83 (m, 2H). 13 C
NMR (126 MHz, CDCl3): δ 200.7, 145.5, 142.9, 134.1, 133.0, 132.1, 128.5, 128.2, 128.0,
127.3, 126.6, 126.5, 118.4, 118.1, 48.9, 39.8, 39.5, 30.4, 25.1. HRMS data: Calc. For C22
H22 O (M + H = 303.174, M + Na = 325.1568), found 303.1710, 325.1540
2e: Isolated as a yellow oil (0.3 mmol scale, 0.061 g, 80%). 1H NMR (500 MHz, CDCl3): δ
7.98 (dd, J = 7.9, 1.2 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.34 Hz, 1H), 7.14
(d, J = 7.6 Hz, 1H), 5.70 (m, 1H), 5.04 (m, 1H), 5.00 (s, 1H), 4.97 (m, 1H), 2.91 (t, J = 6.4
Hz, 2H), 2.46 (ddt, J = 14.14, 6.45, 1.45 Hz, 1H), 2.32 (dd, J = 14.6, 7.0 Hz, 1H), 2.19 (ddd,
J = 14.0, 9.2, 8.2 Hz, 2H), 1.96 (t, J = 6.41 Hz, 2H), 1.63 (s, 3H), 1.50 (s, 3H). 13C NMR
(126 MHz, CDCl3): δ 201.3, 143.2, 134.4, 134.3, 133.0, 132.0, 128.7, 128.0, 126.6, 119.2,
118.0, 48.5, 39.3, 33.1, 30.5, 26.1, 25.2, 18.0. HRMS data: Calc. for C18 H22O (M + H =
255.1749), Found 255.1732; Chiral Resolution: Chiracel OD-H column, mobile phase =
hexanes : 2-propanol 99.7 : 0.3, flow rate = 0.4 μL/min
2f: Isolated as a yellow oil (2.06 mmol scale, 0.441 g, 84%). 1H NMR (500 MHz, CDCl3): δ
7.98 (d, J = 8.14 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.14 (d, J =
7.7 Hz, 1H), 5.41 (m, 1H), 5.33 (m, 1H), 4.73 (s, 1H), 4.60 (s, 1H), 2.91 (m, 2H), 2.66 (d, J
= 13.7 Hz, 1H), 2.35 (dd, J = 14.22, 6.81 Hz, 1H), 2.10 (m, 2H), 1.92 (m, 2H), 1.59 (dd, J =
6.2, 1.2 Hz, 2H), 1.52 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 201.3, 143.2, 142.7, 133.1,
133.0, 132.1, 129.1, 128.6, 128.1, 126.7, 126.6, 126.1, 114.9, 114.9, 47.9, 42.7, 38.8, 30.0,
25.2, 24.5, 18.1. HRMS data: Calc. for C18 H22 O (M + H = 255.1748 and M + Na =
277.1568) found 255.1713 and 277.1593.
2g: Isolated as a yellow oil (0.20 mmol scale, 0.049g, 77%) 1H NMR (500 MHz, CDCl3): δ
8.00 (dd, J = 7.9, 1.2 Hz, 1H), 7.40 (td, J = 7.5, 1.4 Hz, 1H), 7.26 (m, 3H), 7.21 (t, J = 7.43
Hz, 2H), 7.13 (m, 2H), 6.36 (d, J = 15.7 Hz, 1H), 6.12 (m, 1H), 4.76 (s, 1H), 4.63 (s, 1H),
2.95 (dd, J = 12.3, 6.0 Hz, 2H), 2.69 (d, J = 13.6 Hz, 1H), 2.63 (ddd, J = 14.0, 7.2, 1.3 Hz,
1H), 2.31 (ddd, J = 14.0, 7.8, 1.1 Hz, 1H), 2.20 (d, J = 13.7 Hz, 1H), 1.99 (m, 2H), 1.56 (s,
3H). 13C NMR (126 MHz, CDCl3): δ 201.1, 143.1, 142.3, 137.4, 133.5, 133.2, 132.0, 128.7,
128.5, 128.1, 127.2, 126.7, 126.1, 125.8, 115.2, 48.3, 43.0, 39.4, 30.5, 25.3, 24.5.
HRMS data: Calc. C23 H24 O (M + H = 317.1905), found 317.1911
2h: Isolated as a yellow oil (2.0 mmol scale, 0.449 g, 80%). 1H NMR (500 MHz, CDCl3): δ
7.98 (dd, J = 7.9, 1.1 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.5 Hz, 1H), 7.14 (d,
J = 7.6 Hz, 1H), 5.39 (dt, J = 14.9, 7.4 Hz, 1H), 4.94 (dd, J = 15.1, 8.6 Hz, 1H), 4.72 (dd, J =
2.1, 1.5 Hz, 1H), 4.61 (s, 1H), 2.90 (m, 2H), 2.66 (d, J = 13.6 Hz, 1H), 2.35 (ddd, J = 14.0,
7.1, 1.1 Hz, 1H), 2.12 (d, J = 13.7 Hz, 1H), 2.07 (ddd, J = 14.1, 7.6, 0.9 Hz, 1H), 1.92 (m,
2H), 1.54 (s, 3H), 1.28 (m, 1H), 0.58 (m, 2H), 0.24 (m, 2H). 13C NMR (126 MHz, CDCl3):
δ 201.3, 143.2, 142.6, 138.2,133.0, 132.1, 128.6, 128.1, 126.6, 122.5, 114.9, 48.0, 42.7,
38.7, 30.0, 25.2, 24.5, 13.7, 6.6, 6.5. HRMS data: Calc. for C20 H24 O (M + H = 281.1905),
Found 281.1918
2i: Isolated as a yellow oil (2.95 mmol scale, 0.523 g, 66%). 1H NMR (500 MHz, CDCl3): δ
7.99 (dd, J = 7.9, 1.1 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.32 Hz, 1H), 7.14
(d, J = 7.7 Hz, 1H), 5.07 (m, 1H), 4.72 (s, 1H), 4.60 (s, 1H), 2.90 (m, 2H), 2.69 (d, J = 13.6
Hz, 1H), 2.30 (dd, J = 14.7, 6.9 Hz, 1H), 2.15 (m, 1H), 2.11 (d, J = 13.7 Hz, 1H), 1.93 (m,
2H), 1.64 (s, 3H), 1.53 (s, 3H), 1.51 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 201.5, 143.2,
142.7, 134.7, 133.0, 132.1, 128.6, 128.1, 126.6, 119.2, 114.8, 48.4, 42.7, 33.96, 29.9, 26.1,
25.3, 24.5, 18.1. HRMS data: Calc. for C19 H24 O (M + Na = 291.1724), found 291.1693;
Chiral Resolution: Chiracel OD-H column, mobile phase = Hexanes : 2-propanol 99.7 : 0.3,
flow rate = 0.4 μL/min 17.95 min. and 18.45 min.
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2j: Isolated as a yellow oil (1.9 mmol scale, 0.604 g, 95%). 1H NMR (500 MHz, CDCl3): δ
7.97 (m, 1H), 7.38 (t, J = 7.6 Hz 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 5.22
(s, 1H), 4.70 (m, 1H), 4.59 (d, J = 6.8 Hz, 1H), 2.98 (m, 1H), 2.87 (m, 1H), 2.73 (d, J = 13.6
Hz, 1H), 2.37 (d, 1H), 2.03 (m, 9H), 1.51 (s, 2H), 1.18 (s, 2H), 0.77 (s, 2H). 13C NMR (126
MHz, CDCl3): δ 201.3, 144.0, 143.2, 143.1, 143.0, 133.0, 132.9, 132.4, 128.6, 128.5, 128.1,
128.1, 126.6, 126.6, 122.6, 122.5, 114.9, 114.8, 48.9, 48.0, 47.4, 43.7, 43.6, 43.3, 43.0, 40.4,
40.2, 37.9, 31.8, 31.8, 31.7, 31.7, 29.8, 29.4, 26.4, 26.4, 25.6, 25.5, 24.6, 24.6, 21.3, 21.3.
HRMS data: Calc. for C24 H30 O (M + H = 335.2374 and M + Na = 357.2194), found
335.2338 and 357.2197.
2k: Isolated as a yellow oil (0.3 mmol scale, 0.085 g, 88%). 1H NMR (500 MHz, CDCl3): δ
7.98 (dd, J = 7.9, 1.1 Hz, 1H), 7.38 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (t, J = 7.4 Hz, 1H), 7.14 (d,
J = 7.6 Hz, 1H), 5.70 (m, 1H), 5.06 (t, J = 7.35 1H), 4.99 (s, 1H), 4.97 (m, 2H), 2.90 (t, J =
6.3 Hz, 2H), 2.45 (dd, J = 13.9, 7.0 Hz, 1H), 2.33 (dd, J = 14.6, 7.0 Hz, 1H), 2.19 (m, 2H),
1.96 (m, 6H), 1.54 (s, 3H), 1.52 (s, 6H). 13C NMR (126 MHz, CDCl3): δ 201.3, 143.3,
137.9, 134.3, 133.0, 132.0, 131.4, 128.6, 128.0, 126.6, 124.3, 119.3, 118.0, 48.6, 40.0, 39.3,
33.0, 30.4, 26.5, 25.7, 25.3, 17.7, 16.3. HRMS Data: C23 H31 O (M + H = 323.2375) found,
323.2364. Chiral Resolution: Chiracel OD-H column, mobile phase = Hexanes : 2-
propanol 99.7 : 0.3, flow rate = 0.4 μL/min
2l: Isolated as a yellow oil (0.3 mmol scale, 0.054 g, 70%). 1H NMR (500 MHz, CDCl3): δ
7.64 (dd, J = 9.3, 2.7 Hz, 1H), 7.11 (m, 2H), 5.70 (ddt, J = 17.3, 10.2, 7.3 Hz, 1H), 5.01 (m,
2H), 4.75 (s, 1H), 4.61 (s, 1H), 2.87 (m, 2H), 2.65 (d, J = 13.7 Hz, 1H), 2.42 (dd, J = 14.0,
7.1 Hz, 1H), 2.15 (m, 2H), 1.93 (m, 2H), 1.52 (s, 3H). 13C NMR (126 MHz, CDCl3): δ
200.0, 161.7 (d, 249.9 Hz), 142.2, 138.8 (d, J = 2.97 Hz), 133.6, 130.5 (d, J = 7.03 Hz
120.55 (d, J = 22.21 Hz), 118.7, 115.3, 113.9 (d, J = 22.0 Hz), 47.5, 42.7, 40.0, 30.3, 24.5,
24.4. HRMS data: C17 H19 FO (M + Na = 281.1318) found, 281.1322. Chiral Resolution:
Chiracel OD-H column, mobile phase = Hexanes : 2-propanol 99.9 : 0.1, flow rate = 0.4 μL/
min
2m: Isolated as a yellow oil (0.3 mmol scale, 0.045 g, 55%). 1H NMR (500 MHz, CDCl3): δ
7.96 (d, J = 8.8 Hz, 1H), 6.76 (dd, J = 8.8, 2.5 Hz, 1H), 6.59 (d, J = 2.5 Hz, 1H), 5.72 (m,
1H), 5.02 (dm, J = 3.29 Hz 1H), 4.99 (dm, J = 11.31 Hz 1H), 4.73 (s, 1H), 4.61 (s, 1H), 3.78
(s, 3H), 2.88 (m, 2H), 2.67 (d, J = 13.6 Hz, 1H), 2.42 (dd, J = 14.0, 7.0 Hz, 1H), 2.15 (m,
1H), 2.11 (d, J = 13.7 Hz, 1H), 1.95 (ddd, J = 14.0, 8.9, 5.2 Hz, 1H), 1.88 (ddd, J = 14.0, 8.9,
5.2 Hz 1H), 1.53 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 199.8, 163.4, 145.6, 142.6, 134.1,
130.6, 125.7, 118.3,114.9, 113.3, 112.3, 55.4, 47.4, 42.9, 40.4, 30.2, 25.6, 24.4.
HRMS data: C18 H22 O2 (M + Na = 293.1517), found 293.1545. Chiral Resolution:
Chiracel OD-H column, mobile phase = Hexanes : 2-propanol 99.7 : 0.3, flow rate = 1 μL/
min
2n:14,41 Isolated as a yellow oil (0.25 mmol scale, 0.046 g, 75%). 1H NMR (500 MHz,
CDCl3): δ 7.40 (s, 1H), 6.76 (s, 1H), 5.71 (ddt, J = 16.6, 10.5, 7.4 Hz, 1H), 5.01 (m, 1H),
4.98 (dm, J = 9.53 Hz, 1H), 3.78 (s, 3H), 2.76 (m, 2H), 2.35 (dd, J = 13.8, 7.3 Hz, 1H), 2.30
(s, 3H), 2.18 (dd, J = 13.8, 7.5 Hz, 1H), 1.95 (ddd, J = 13.6, 7.1, 5.4 Hz, 1H), 1.80 (m, 1H),
1.09 (s, 3H). 13C NMR(126 MHz, CDCl3): δ 202.6, 156.6, 136.8, 134.1, 132.1, 129.4,
119.6, 118.1, 115.0, 55.6, 44.3, 40.9, 32.8, 21.8, 21.5, 18.9. Chiral Resolution: Chiracel OD-
H column, mobile phase = Hexanes : 2-propanol 99.7 : 0.3, flow rate = 0.4 μL/min.
2o:6 Isolated as a yellow oil (0.45 mmol scale, 0.074 g, 88%). 1H NMR (500 MHz, CDCl3):
δ 7.55 (d, J = 7.7 Hz, 1H), 7.39 (td, J = 7.5, 1.1 Hz, 1H), 7.22 (d, J = 7.7 Hz, 1H), 7.17 (t, J =
7.5 Hz, 1H), 5.45 (m, 1H), 4.87 (d, J = 17.0 Hz, 1H), 4.81 (d, J = 10.1 Hz, 1H), 2.97 (d, J =
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17.2 Hz, 1H), 2.64 (d, J = 17.2 Hz, 1H), 2.19 (ddt, J = 13.6, 6.7, 1.2 Hz, 1H), 2.10 (dd, J =
13.7, 8.0 Hz, 1H), 1.02 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 210.8, 152.6, 135.9, 134.9,
133.9, 127.4, 126.6, 124.3, 118.4, 48.8, 42.5, 39.4, 23.8.
2p:6 Isolated as a yellow oil (2.5 mmol scale, 0.496 g, 93%). 1H NMR (500 MHz, CDCl3): δ
7.37 (m, 1H), 7.27 (dd, J = 4.9, 0.9 Hz, 2H), 7.13 (d, J = 7.5 Hz, 1H), 5.75 (ddt, J = 16.3,
10.7, 7.5 Hz, 1H), 5.07 (m, 1H), 5.04 (dm, J = 8.97 Hz, 1H), 2.80 (m, 2H), 2.34 (ddd, J =
7.1, 3.2, 2.1 Hz, 2H), 1.93 (m, 2H), 1.78 (m, 1H), 1.62 (m, 2H), 1.20 (s, 3H). 13C NMR (126
MHz, CDCl3): δ 214.4, 141.6, 137.2, 133.7, 130.7, 128.4, 127.1, 126.5, 118.3, 49.1, 43.9,
34.5, 32.9, 22.8, 22.3.
2q: Isolated as a yellow oil (23.5 mmol scale, 6.2 g, 86%). 1H NMR (500 MHz, CDCl3): δ
8.00 (dd, J = 7.9, 1.1 Hz, 1H), 7.39 (td, J = 7.5, 1.4 Hz, 1H), 7.23 (m, 5H), 7.12 (m, 2H),
6.35 (d, J = 15.8 Hz, 1H), 6.12 (m, 1H), 5.73 (m, 1H), 5.03 (dd, J = 3.2, 2.0 Hz, 1H), 5.00
(ddd, J = 4.5, 2.0, 1.2 Hz, 1H), 2.93 (m, 2H), 2.62 (ddd, J = 14.0, 7.2, 1.3 Hz, 1H), 2.47 (dd,
J = 14.0, 7.1 Hz, 1H), 2.34 (ddd, J = 14.0, 7.8, 1.1 Hz, 1H), 2.25 (dd, J = 14.0, 7.5 Hz, 1H),
2.01 (m, 2H). 13C NMR (126 MHz, CDCl3): δ 200.9, 143.2, 137.4, 133.8, 133.3, 133.2,
131.8, 128.7, 128.5, 128.1, 127.2, 126.7, 126.1, 125.8, 118.4, 48.3, 39.3, 38.5, 30.7, 25.2.
HRMS data: Calc. for C22H23O: (M + H = 303.1749), Found 303.1729
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Scheme 1. Asymmetric allylic alkylation (AAA) of tetralones
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Scheme 2. Deacylative allylation (DaA)
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Scheme 3. Synthesis of Clive-Stoltz intermediate 2nen route to (+)-hamigeran
Grenning et al. Page 13














































































































































































































standard conditions: (0.2-0.3 mmol scale) 1:1 acetyltetralone : allyl alcohol, 2 equiv. NaH, 2.5 mol% Pd(PPh3)4, 12 h, 0.075M
b
≥0.5 gram scale: 1 mol% Pd(PPh3)4, 40°C 5-12h, 0.5M
c
starting material was 4:1 mixture of E/Z crotyl isomers and is reflected in the product
d
standard conditions for 48h
e
23.5 mmol scale, 1:1 acetyl tetralone : allyl alcohol, 1.5 equiv. NaH, THF, 0°C–rt 0.5 M, 16-18h
f
average of 2 runs by 2 different experimenters
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Table 4
Synthesis of enantioenriched 1,6-dienes via DaA
(a) conditions: 0.2-0.3 mmol 1.05 : 1 acetyltetralone : allylic alcohol, 0.075M in THF, 2 equiv. NaH, premix Pd/L for 5 min @ 40 °C
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